Agios Pharmaceuticals (NASDAQ:AGIO) Posts Earnings Results, Misses Estimates By $0.05 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05), Zacks reports. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Agios Pharmaceuticals Price Performance

AGIO stock traded down $0.49 during trading on Thursday, reaching $33.53. 61,899 shares of the stock traded hands, compared to its average volume of 740,619. The business’s 50 day moving average price is $34.45 and its 200-day moving average price is $43.14. Agios Pharmaceuticals has a 52-week low of $26.50 and a 52-week high of $62.58. The firm has a market capitalization of $1.92 billion, a PE ratio of 2.96 and a beta of 0.88.

Analysts Set New Price Targets

AGIO has been the subject of a number of analyst reports. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank boosted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Royal Bank of Canada lifted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $56.33.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.